سعر انوهيب 4500وحدة/0.45مل 10 سرنجة معبأة 4,500 anti-Xa وحدة دولية/0.45 مل 2022

Innohep (4,500 anti-Xa IU/0.45 ml (10,000 IU/ml)) solution for injection in pre-filled syringe, 10 pre-filled syringes: tinzaparin sodium, a low molecular weight heparin by LEO Pharma, used for prophylaxis of venous thromboembolism and anticoagulation of haemodialysis circuits.

• Prophylaxis of venous thromboembolism in adults undergoing surgery, particularly orthopaedic, general or oncological surgery.Population: Adultselectronic medicines compendium (emc), UK
• Prophylaxis of venous thromboembolism in non-surgical adults immobilised due to acute medical illness (e.g. acute heart failure, acute respiratory failure, severe infections, active cancer, exacerbation of rheumatic diseases).Population: Adultselectronic medicines compendium (emc), UK
• Prevention of clotting in extracorporeal circuits during haemodialysis and haemofiltration in adults.Population: Adultselectronic medicines compendium (emc), UK

• Common: haemorrhage, haematoma, anaemia (incl. haemoglobin decreased) and injection-site reactions. Uncommon: thrombocytopenia type I, hypersensitivity, bruising/purpura, increased liver enzymes, dermatitis, rash, pruritus. Rare: HIT type II, thrombocytosis, anaphylaxis, hyperkalaemia, toxic skin eruption incl. Stevens-Johnson syndrome, skin necrosis, angioedema, urticaria, osteoporosis with long-term use, priapism.International label, same formulation · electronic medicines compendium (emc), UK

• Hypersensitivity to tinzaparin or any excipient.International label, same formulation · electronic medicines compendium (emc), UK
• Current or history of immune-mediated heparin-induced thrombocytopenia (type II).International label, same formulation · electronic medicines compendium (emc), UK
• Active major haemorrhage or conditions predisposing to major haemorrhage.International label, same formulation · electronic medicines compendium (emc), UK

• Haemorrhage risk: use with caution; avoid or carefully monitor combination with drugs affecting platelets or coagulation; avoid intramuscular injections.International label, same formulation · electronic medicines compendium (emc), UK
• Heparin-induced thrombocytopenia: measure platelet count before and periodically during treatment; discontinue if HIT type II develops.International label, same formulation · electronic medicines compendium (emc), UK
• Hyperkalaemia via aldosterone suppression, particularly with diabetes, chronic renal failure, metabolic acidosis, potassium-raising drugs or long-term use; monitor potassium in patients at risk.International label, same formulation · electronic medicines compendium (emc), UK

• Drugs affecting coagulation or platelet function (aspirin and other NSAIDs, thrombolytics, vitamin K antagonists, activated protein C, direct factor Xa and IIa inhibitors)May enhance the anticoagulant effect of tinzaparin; avoid or monitor carefully.electronic medicines compendium (emc), UK

• Data from more than 2,200 pregnancy outcomes show no malformative or feto/neonatal toxicity; tinzaparin does not cross the placenta and can be used in all trimesters if clinically needed, under specialist involvement; not recommended in pregnant women with prosthetic heart valves.International label, same formulation · electronic medicines compendium (emc), UK
• Passage into breast milk is expected to be very low and oral absorption by the infant very unlikely; tinzaparin can be used during breastfeeding.International label, same formulation · electronic medicines compendium (emc), UK

• Tinzaparin sodium: Potentiates antithrombin III inhibition of activated coagulation factors, primarily factor Xa (anti-Xa/anti-IIa ratio 1.5-2.5); mass-average molecular mass about 6,500 daltons (UK SmPC 5.1).